Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data
<i>Background and Objectives</i>: This study aimed to investigate osteoporosis-related treatments and the overall anticancer drug treatment tendencies, with a focus on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), in Korean patients with breast cancer fro...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/9/1505 |
| _version_ | 1827725387642175488 |
|---|---|
| author | Yen Min Wang Yu-Cheol Lim Deok-Sang Hwang Yoon Jae Lee In-Hyuk Ha Ye-Seul Lee |
| author_facet | Yen Min Wang Yu-Cheol Lim Deok-Sang Hwang Yoon Jae Lee In-Hyuk Ha Ye-Seul Lee |
| author_sort | Yen Min Wang |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: This study aimed to investigate osteoporosis-related treatments and the overall anticancer drug treatment tendencies, with a focus on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), in Korean patients with breast cancer from 2010 to 2019. <i>Materials and Methods</i>: Data were obtained from the Health Insurance Review and Assessment Service. Patients with breast cancer (International Classification of Diseases, 10th Revision code: C50) as a principal diagnosis at least once from 2010 to 2019 were included. Those with osteoporosis (M80, M81, or M82) as a principal or sub-diagnosis or those who received osteoporosis treatment at least once were categorized as the osteoporosis-related treatment group, and others as the non-osteoporosis-related treatment group. The trends of drug prescriptions and treatment costs in patient groups were evaluated using descriptive statistics. <i>Results</i>: Among all included patients, those aged 45–54 years (40.20%) without osteoporosis treatment and those aged 55–64 years (34.11%) with osteoporosis treatment were the most common. SERM was the most commonly prescribed anticancer drug (29.20%) in the entire patient group, followed by AIs (20.83%). Patients without osteoporosis treatment had the highest prescription rate of SERM (31.48%), and those with osteoporosis treatment had a higher prescription rate of AIs (34.28%). Additionally, SERM and AIs were prescribed most frequently before and after the age of 55 years, respectively, regardless of the presence of treatment. <i>Conclusions</i>: This study found that osteoporosis-related treatment and patient age were associated with anticancer drug prescriptions. The present findings would help clinicians and researchers in the clinical diagnosis and treatment of breast cancer. |
| first_indexed | 2024-03-10T22:28:39Z |
| format | Article |
| id | doaj.art-1248c8e836bf451ab47a3939e598e881 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T22:28:39Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-1248c8e836bf451ab47a3939e598e8812023-11-19T11:50:50ZengMDPI AGMedicina1010-660X1648-91442023-08-01599150510.3390/medicina59091505Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample DataYen Min Wang0Yu-Cheol Lim1Deok-Sang Hwang2Yoon Jae Lee3In-Hyuk Ha4Ye-Seul Lee5Jaseng Hospital of Korean Medicine, 536 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of KoreaJaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 2F, 540 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of KoreaDepartment of OB & GY in Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02453, Republic of KoreaJaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 2F, 540 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of KoreaJaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 2F, 540 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of KoreaJaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 2F, 540 Gangnam-daero, Gangnam-gu, Seoul 06110, Republic of Korea<i>Background and Objectives</i>: This study aimed to investigate osteoporosis-related treatments and the overall anticancer drug treatment tendencies, with a focus on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), in Korean patients with breast cancer from 2010 to 2019. <i>Materials and Methods</i>: Data were obtained from the Health Insurance Review and Assessment Service. Patients with breast cancer (International Classification of Diseases, 10th Revision code: C50) as a principal diagnosis at least once from 2010 to 2019 were included. Those with osteoporosis (M80, M81, or M82) as a principal or sub-diagnosis or those who received osteoporosis treatment at least once were categorized as the osteoporosis-related treatment group, and others as the non-osteoporosis-related treatment group. The trends of drug prescriptions and treatment costs in patient groups were evaluated using descriptive statistics. <i>Results</i>: Among all included patients, those aged 45–54 years (40.20%) without osteoporosis treatment and those aged 55–64 years (34.11%) with osteoporosis treatment were the most common. SERM was the most commonly prescribed anticancer drug (29.20%) in the entire patient group, followed by AIs (20.83%). Patients without osteoporosis treatment had the highest prescription rate of SERM (31.48%), and those with osteoporosis treatment had a higher prescription rate of AIs (34.28%). Additionally, SERM and AIs were prescribed most frequently before and after the age of 55 years, respectively, regardless of the presence of treatment. <i>Conclusions</i>: This study found that osteoporosis-related treatment and patient age were associated with anticancer drug prescriptions. The present findings would help clinicians and researchers in the clinical diagnosis and treatment of breast cancer.https://www.mdpi.com/1648-9144/59/9/1505aromatase inhibitorsbreast cancerosteoporosisselective estrogen receptor modulatorantineoplastic agents |
| spellingShingle | Yen Min Wang Yu-Cheol Lim Deok-Sang Hwang Yoon Jae Lee In-Hyuk Ha Ye-Seul Lee Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data Medicina aromatase inhibitors breast cancer osteoporosis selective estrogen receptor modulator antineoplastic agents |
| title | Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data |
| title_full | Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data |
| title_fullStr | Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data |
| title_full_unstemmed | Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data |
| title_short | Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data |
| title_sort | osteoporosis associated with breast cancer treatments based on types of hormonal therapy a cross sectional study using korean national sample data |
| topic | aromatase inhibitors breast cancer osteoporosis selective estrogen receptor modulator antineoplastic agents |
| url | https://www.mdpi.com/1648-9144/59/9/1505 |
| work_keys_str_mv | AT yenminwang osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata AT yucheollim osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata AT deoksanghwang osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata AT yoonjaelee osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata AT inhyukha osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata AT yeseullee osteoporosisassociatedwithbreastcancertreatmentsbasedontypesofhormonaltherapyacrosssectionalstudyusingkoreannationalsampledata |